FDA Delays Cytisinicline Approval Over Manufacturing Issues
Event summary
- Achieve Life Sciences received a Complete Response Letter from the FDA for its cytisinicline NDA, citing manufacturing deficiencies at a third-party facility.
- No clinical efficacy or safety issues were identified with cytisinicline.
- The company plans to resubmit its NDA in Q4 2026, targeting FDA approval in H1 2027.
The big picture
The FDA's Complete Response Letter highlights ongoing challenges in pharmaceutical manufacturing compliance, a critical hurdle for late-stage biotech companies. Achieve's ability to pivot to Adare Pharma Solutions as its primary manufacturer will be key to overcoming this regulatory setback. The delay underscores the importance of robust supply chain management in drug approval processes.
What we're watching
- Regulatory Pathway
- Whether Achieve can successfully address the FDA's manufacturing concerns and secure approval in H1 2027.
- Commercial Readiness
- The pace at which Achieve advances its commercial readiness for cytisinicline launch post-approval.
- Market Opportunity
- How the delay impacts competitive positioning in the nicotine dependence treatment market.
Related topics